In Vitro Models From Pediatric Brain Tumors (PBTS23)

In Vitro Models Derived From Pediatric Glial Tumors and Pediatric Embryonal Tumors for Drug Testing and Molecular Studies

Tumors of the Central Nervous System (CNS) represent the leading cause of cancer-related deaths in children. Current treatment options are not curative for most malignant histologies, and intense preclinical and clinical research are necessary to develop more effective therapeutic interventions against these tumors, most of which meet the FDA definition for orphan diseases. The majority of malignant CNS tumors in children and adolescents belong to two broad histologic tumor entities: those of glial origin, such as high-grade glioma (HGG)and ependymoma (EPN), and those of neuronal origin, also identified as embryonal tumors, that include medulloblastoma and AT/RT(1). Over the last few years, whole-genome sequencing, gene-expression profiling and genome-wide methylation studies have greatly deepened our understanding of the biology and genetics of these tumors, allowing for robust stratification in clinically relevant molecular subgroups. The advancement of single-cell omics over the last decade have highlighted the enormous heterogeneity of tumors, a complex mixture of co-existing cancer subclones and supportive normal cell populations.

However, current treatments have remained largely static, and 5-year survival rate for children with malignant CNS tumors only achieves a modest 57.5%.

More effective treatment strategies should include novel chemotherapeutic agents that take into account high intrinsic tumor heterogeneity as well as the complex regulations of transcriptional and translational mechanisms that control protein expression. Identification of novel drugs and treatment strategies is further limited by the paucity of appropriate preclinical models, which mirror the molecular characteristics of distinct tumor subgroups.

We propose to establish patient-derived in vitro models to predict chemotherapeutic drug sensitivity/resistance in malignant pediatric CNS tumors. Next, we propose to perform molecular analyses in tissues of pediatric CNS tumors to determine whether in vitro findings have clinical correlates.

Study Overview

• Status: Not yet recruiting
• Conditions: Ependymoma; Medulloblastoma; Glioma, Malignant
• Intervention / Treatment: Other: other

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

• Study Contact: Name: Antonio Ruggiero, prof; Phone Number: 00390630155155; Email: antonio.ruggiero@unicatt.it
• Study Contact Backup: Name: Tiziana Servidei, PhD; Phone Number: 00390630155155; Email: tiziana.servidei@guest.policlinicogemelli.it

Study Locations

• Italy
  • Rome
    • Roma, Rome, Italy, 00168
      • Pediatric Oncology Unit- Fondazione Policlinico Gemelli IRCCS
      • Contact: Antonio Ruggiero, MD; Phone Number: 0039063015155; Email: antonio.ruggiero@policlinicogemelli.it

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Children and young adults

Description

Inclusion Criteria:

• Children and young adults who undergo standard surgical resection for suspected primary brain tumors or recurrent brain tumors
• signed written informed consent

Exclusion Criteria:

• no informed consent

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
1) Establishment of in vitro models derived from pediatric tumors of the CNS, which more faithfully mirror the molecular features and heterogeneity of pediatric EPNs.	Collection and storage of snap-frozen pediatric brain tumor samples (tumor specimens and blood samples). Generation of patient-derived cell lines.	48 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
2) Preclinical drug testing, to explore the chemotherapeutic potential of selected standard and molecularly-targeted agents.	The models that will be prospectively established in the objective number 1 and the already commercially available models will be used for preclinical in vitro studies with agents belonging to imipridones and DHODH inhibitors	24 months
3) Molecular studies on pediatric brain tumor tissues, to determine whether the cellular, molecular and biochemical findings in in vitro models have clinical correlates.	To determine whether the findings in preclinical models have clinical correlates, tumor samples that will prospectively be collected and stored in the Biobank of Fondazione Policlinico Universitario Gemelli will be analyzed for the expression of selected biomarkers. RNA extraction, reverse transcription and real-time PCR will be performed	36 months

Collaborators and Investigators

• Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Investigators: Principal Investigator: Antonio Ruggiero, prof, Fondazione Policlinico Gemelli IRCCS

Study record dates

Study Major Dates

• Study Start (Estimated): September 1, 2024
• Primary Completion (Estimated): June 30, 2028
• Study Completion (Estimated): June 30, 2029

Study Registration Dates

• First Submitted: July 8, 2024
• First Submitted That Met QC Criteria: July 8, 2024
• First Posted (Actual): July 12, 2024

Study Record Updates

• Last Update Posted (Actual): July 12, 2024
• Last Update Submitted That Met QC Criteria: July 8, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroectodermal Tumors, Primitive; Glioma; Ependymoma; Medulloblastoma
• Other Study ID Numbers: 6351

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No